Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25173725 | 0.85 | HIF1A (0.56) | ADORA2AHIF1AADORA3PAX8ADORA1 | |
| SCHEMBL25173767 | 0.85 | HIF1A (0.56) | ADORA2AHIF1AADORA3PAX8ADORA1 | |
| SCHEMBL3247314 | 0.83 | ADORA3 (0.57) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL9386366 | 0.83 | ADORA3 (0.57) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL25176202 | 0.78 | TSHR (0.52) | ADORA2AHIF1AADORA3PAX8ADORA1 | |
| SCHEMBL25173559 | 0.78 | TSHR (0.52) | ADORA2AHIF1AADORA3PAX8ADORA1 | |
| SCHEMBL25176651 | 0.78 | TSHR (0.52) | ADORA2AHIF1AADORA3PAX8ADORA1 | |
| SCHEMBL30411592 | 0.70 | SLC29A1 (0.50) | ADORA2AADORA3ADORA1 | |
| SCHEMBL13382546 | 0.67 | AHCY (0.74) | ADORA2AADORA2BHIF1AAHCYTMEM97 | |
| SCHEMBL5967720 | 0.67 | ADORA2A (1.00) | ADORA2AADORA2BHIF1AAHCYTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | claimed |
| EP-0896063-B9 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| EP-0896063-B1 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| EP-0601092-B2 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SYNGENTA PARTICIPATIONS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-5994629-A | Positive selection | NOVARTIS AG (CH) | 1999-11-30 | — | — | US | disclosed |
| EP-0601092-B1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | NOVARTIS AG (CH) | 1999-07-07 | — | — | EP | disclosed |
| EP-0896063-A2 | Method for the selection of genetically transformed cells and compounds for use in the method | Novartis AG (CH) | 1999-02-10 | — | — | EP | disclosed |
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | disclosed |